Premyelinating Oligodendrocytes in Chronic Lesions of Multiple Sclerosis
Open accessThe DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Abstract
Background Multiple sclerosis is an inflammatory disease of the central nervous system that destroys myelin, oligodendrocytes, and axons. Since most of the lesions of multiple sclerosis are not remyelinated, enhancement of remyelination is a possible therapeutic strategy that could perhaps be achieved with the transplantation of oligodendrocyte-producing cells into the lesions. We investigated the frequency distribution and configuration of oligodendrocytes in chronic lesions of multiple sclerosis to determine whether these factors limit remyelination. Methods Forty-eight chronic lesions obtained at autopsy from 10 patients with multiple sclerosis were examined immunocytochemically for oligodendrocytes and oligodendrocyte progenitor cells. Using confocal microscopy, we examined the three-dimensional relations between axons and the processes of premyelinating oligodendrocytes. Results Thirty-four of the 48 chronic lesions of multiple sclerosis contained oligodendrocytes with multiple extended processes that associated with demyelinated axons but failed to myelinate them. These axons were dystrophic and contained multiple swellings. In some regions, the densities of premyelinating oligodendrocytes (25 per square millimeter of tissue) were similar to those in the developing rodent brain (23 per square millimeter). In the patients with disease of long duration (more than 20 years), there were fewer lesions with premyelinating oligodendrocytes (P Conclusions Premyelinating oligode…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The efficacy of remyelination has been shown to depend on multiple factors such as, age, disease duration and lesion location.”
From BCAS1-positive oligodendrocytes enable efficient cortical remyelination in multiple sclerosis (2025) · cites this paper as [12]
In the citing paper
“The long‐term consequence of demyelination in the CNS is axonal damage and neurodegeneration (Chang et al. 2002) in both white and gray matter lesions, leading to progressive disease.”
From Depletion of Microglia Increases Cortical Oligodendrocyte Density During Remyelination (2026) · cites this paper as Chang et al. 2002
In the citing paper
“In MS lesions, OPCs are recruited but fail to differentiate into myelinating OLs, suggesting that remyelination is blocked at the differentiation and remyelination stage rather than during OPC recruitment (Chang et al., 2002; Kuhlmann et al., 2008; Wolswijk, 1998).”
From miR-219 Cooperates with miR-338 in Myelination and Promotes Myelin Repair in the CNS (2017) · cites this paper as Chang et al., 2002
In the citing paper
“In MS lesions, OPCs are recruited but fail to differentiate into myelinating OLs, suggesting that remyelination is blocked at the differentiation and remyelination stage rather than during OPC recruitment (Chang et al., 2002; Kuhlmann et al., 2008; Wolswijk, 1998).”
From miR-219 Cooperates with miR-338 in Myelination and Promotes Myelin Repair in the CNS (2017) · cites this paper as Chang et al., 2002
In the citing paper
“Furthermore, oligodendrocyte progenitor cells (OPCs) are a population of adult stem cells responsible for mediating CNS myelin repair in demyelinating conditions such as MS [113,114].”
From Ageing, Cellular Senescence and Neurodegenerative Disease (2018) · cites this paper as [114]
Citations
Cites
Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)
Kurtzke, J. F. (1983) · Neurology · doi:10.1212/wnl.33.11.1444 · Cited by 15,011
Axonal transection in the lesions of multiple sclerosis
Trapp, B. D., Peterson, J., Ransohoff, R. M., Rudick, R., Mörk, S., & Bö, L. (1998) · New England Journal of Medicine · doi:10.1056/nejm199801293380502 · Cited by 4,029
Self-citationNoseworthy, J. H., Lucchinetti, C., Rodriguez, M., & Weinshenker, B. G. (2000) · New England Journal of Medicine · doi:10.1056/nejm200009283431307 · Cited by 2,899
Raff, M. C., Miller, R. H., & Noble, M. (1983) · Nature · doi:10.1038/303390a0 · Cited by 2,030
Axonal damage in acute multiple sclerosis lesions
Ferguson, B. (1997) · Brain · doi:10.1093/brain/120.3.393 · Cited by 1,532
WEINSHENKER, B. G., BASS, B., RICE, G. P. A., NOSEWORTHY, J., CARRIERE, W., BASKERVILLE, J., & EBERS, G. C. (1989) · Brain · doi:10.1093/brain/112.1.133 · Cited by 1,452
Cell death and control of cell survival in the oligodendrocyte lineage
Barres, B. A., Hart, I. K., Coles, H. S. R., Burne, J. F., Voyvodic, J. T., Richardson, W. D., & Raff, M. C. (1992) · Cell · doi:10.1016/0092-8674(92)90531-g · Cited by 1,345
Multiple Sclerosis and Chronic Autoimmune Encephalomyelitis
Kornek, B., Storch, M. K., Weissert, R., Wallstroem, E., Stefferl, A., Olsson, T., Linington, C., Schmidbauer, M., & Lassmann, H. (2000) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64537-3 · Cited by 921
The oligodendrocyte and its many cellular processes
PFEIFFER, S., WARRINGTON, A., & BANSAL, R. (1993) · Trends in Cell Biology · doi:10.1016/0962-8924(93)90213-k · Cited by 737
NG2-Positive Oligodendrocyte Progenitor Cells in Adult Human Brain and Multiple Sclerosis Lesions
Chang, A., Nishiyama, A., Peterson, J., Prineas, J., & Trapp, B. D. (2000) · The Journal of Neuroscience · doi:10.1523/jneurosci.20-17-06404.2000 · Cited by 712
Self-citation
Research works printed but not linked: 2
- 10.1056/nejm199801293380610 · doi:10.1056/nejm199801293380610 · Paper page
- Prineas JW, 1989, Lab Invest, 61, 489
Cited by
Items 301–400 of 1,000
Stem cells for the treatment of myelin loss
Keirstead, H. S. (2005) · Trends in Neurosciences · doi:10.1016/j.tins.2005.09.008 · Cited by 68
Girolamo, F., Ferrara, G. B., Strippoli, M., Rizzi, M., Errede, M., Trojano, M., Perris, R., Roncali, L., Svelto, M., Mennini, T., et al. (2011) · Neurobiology of Disease · doi:10.1016/j.nbd.2011.05.021 · Cited by 69
“…differentiation and/or axon-wrapping capacities (Butovsky et al., 2006; Chen et al., 2009; Höftberger et al., 2010; Huang et al., 2011; Jurynczyk et al., 2008; Kremer et al., 2011; Mi et al., 2005), modified interactions with the dystrophic axons (Chang et al., 2002; John et al., 2002).”
Hammond, T. R., McEllin, B., Morton, P. D., Raymond, M., Dupree, J., & Gallo, V. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.11.002 · Cited by 60
“However, stalled OPC differentiation is frequently found in patients with progressive MS (Chang et al., 2002; Wolswijk, 1998), possibly due to the aberrant expression of signals within the demyelinated lesions (Franklin and Ffrench-Constant, 2008).”
BackgroundFan, H.-B., Chen, L.-X., Qu, X.-B., Ren, C.-L., Wu, X.-X., Dong, F.-X., Zhang, B.-L., Gao, D.-S., & Yao, R.-Q. (2017) · Scientific Reports · doi:10.1038/srep41407 · Cited by 62
Metabolic defects in multiple sclerosis
Adiele, R. C., & Adiele, C. A. (2017) · Mitochondrion · doi:10.1016/j.mito.2017.12.005 · Cited by 67
Current advancements in promoting remyelination in multiple sclerosis
Kremer, D., Akkermann, R., Küry, P., & Dutta, R. (2018) · Multiple Sclerosis Journal · doi:10.1177/1352458518800827 · Cited by 67
Oligodendrocyte Intrinsic miR-27a Controls Myelination and Remyelination
Tripathi, A., Volsko, C., Garcia, J. P., Agirre, E., Allan, K. C., Tesar, P. J., Trapp, B. D., Castelo-Branco, G., Sim, F. J., & Dutta, R. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.09.020 · Cited by 60
Self-citationReduced cerebrospinal fluid BACE1 activity in multiple sclerosis
Mattsson, N., Axelsson, M., Haghighi, S., Malmeström, C., Wu, G., Anckarsäter, R., Sankaranarayanan, S., Andreasson, U., Fredrikson, S., Gundersen, A., et al. (2009) · Multiple Sclerosis Journal · doi:10.1177/1352458508100031 · Cited by 61
“Additionally, BACE1 activity decreased over time in patients with RRMS towards SPMS-like levels, indicating a successive loss of BACE1 function that might explain the known reduction in remyelinating capacity in late disease stages [2].”
BackgroundChu, T., Shields, L. B. E., Zhang, Y. P., Feng, S., Shields, C. B., & Cai, J. (2017) · The Neuroscientist · doi:10.1177/1073858416685690 · Cited by 64
Srivastava, T., Diba, P., Dean, J. M., Banine, F., Shaver, D. C., Hagen, M. W., Gong, X., Su, W., Emery, B., Marks, D. L., et al. (2018) · Journal of Clinical Investigation · doi:10.1172/jci94158 · Cited by 64
“In chronic human neonatal WMI (17) and MS (33), myelination failure arises when OL lineage progression is blocked at the late OPC (preOL) stage.”
BackgroundDistinctive Properties of Human Adult Brain-Derived Myelin Progenitor Cells
Ruffini, F., Arbour, N., Blain, M., Olivier, A., & Antel, J. P. (2004) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)63266-x · Cited by 64
“Phenotypic profiles of such cells include: O4 GalC NG2 ,(13) PDGF-R GalC ,(14,15) PDGF-R , NG2 ,(16) and PLP pre-OLGs.(17) These cells do not however appear to be overrepresented nor are they consistently proliferating in the lesions.”
BackgroundNiu, J., Yu, G., Wang, X., Xia, W., Wang, Y., Hoi, K. K., Mei, F., Xiao, L., Chan, J. R., & Fancy, S. P. J. (2021) · Neuron · doi:10.1016/j.neuron.2021.07.018 · Cited by 75
“(I) EM of remyelination at 50 dpl in PDGFRa-creER:RZfl/fl and RZfl/fl control mic (J) g-ratio analyses of remyelination at 14, 21, and 50 dpl (scatterplot displays g PDGFRa-creER:RZfl/fl and RZfl/fl/ control lesions (solid lines show linear trend li (K) MAG+ mRNA expressing OLs at 14 dpl following lysolecithin-induced…”
InfluentialKumar, S., Biancotti, J. C., Yamaguchi, M., & de Vellis, J. (2006) · Neurochemical Research · doi:10.1007/s11064-006-9208-6 · Cited by 62
“Demyelinated lesions in human diseases and in rodent demyelinating models contain OL progenitors (OLPs) and immature OLs with potential for remyelination [1, 2, 3], yet axons remain demyelinated under chronic conditions [4].”
BackgroundCimini, A., Bernardo, A., Cifone, G., Di Muzio, L., & Di Loreto, S. (2003) · Glia · doi:10.1002/glia.10143 · Cited by 60
“In fact, it has been demonstrated that in the chronic lesions of MS premyelinating OLs fail to myelinate axons (Wolswijk, 1998; Chang et al., 2000, 2002).”
BackgroundZhou, Y., Flint, N. C., Murtie, J. C., Le, T. Q., & Armstrong, R. C. (2006) · Glia · doi:10.1002/glia.20410 · Cited by 59
“Signals regulating OPC differentiation are also important to understand in the context of demyelinated lesions since OPCs and premyelinating oligodendrocytes may be present in MS lesions yet often fail to remyelinate effectively (Chang et al., 2000, 2002).”
BackgroundZhang, J., Zhang, Z. G., Lu, M., Zhang, Y., Shang, X., & Chopp, M. (2019) · Neurobiology of Disease · doi:10.1016/j.nbd.2019.01.019 · Cited by 59
CNS myelination requires VAMP2/3-mediated membrane expansion in oligodendrocytes
Lam, M., Takeo, K., Almeida, R. G., Cooper, M. H., Wu, K., Iyer, M., Kantarci, H., & Zuchero, J. B. (2022) · Nature Communications · doi:10.1038/s41467-022-33200-4 · Cited by 56
Olig1 Acetylation and Nuclear Export Mediate Oligodendrocyte Development
Dai, J., Bercury, K. K., Jin, W., & Macklin, W. B. (2015) · Journal of Neuroscience · doi:10.1523/jneurosci.0882-15.2015 · Cited by 60
“Nevertheless, only minimal remyelination occurs and it appears that OPC maturation is particularly vulnerable in MS (Wolswijk, 1998, 2000; Chang et al., 2002; Kuhlmann et al., 2008).”
Vallée, A., Lecarpentier, Y., Guillevin, R., & Vallée, J.-N. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19041212 · Cited by 60
The Anti-Aging Protein Klotho Enhances Remyelination Following Cuprizone-Induced Demyelination
Zeldich, E., Chen, C.-D., Avila, R. L., Medicetty, S., & Abraham, C. R. (2015) · Journal of Molecular Neuroscience · doi:10.1007/s12031-015-0598-2 · Cited by 63
“2012), while the majority of chronically demyelinated lesions in white matter demonstrate restricted remyelination due to a reduced recruitment of OPCs, the failure of OPCs to produce mature oligodendrocytes, and the insufficient production of myelin sheath by OLs (Trapp et al. 1997; Wolswijk 2000; Chang et al. 2002;…”
InfluentialNG2-positive glia in the human central nervous system
Staugaitis, S. M., & Trapp, B. D. (2009) · Neuron Glia Biology · doi:10.1017/s1740925x09990342 · Cited by 58
“Bipolar cells have also been reported by others (Filipovic et al., 2002; Reynolds et al., 2002).”
BackgroundSelf-citationStem Cell-Based Therapies for Multiple Sclerosis: Current Perspectives
Cuascut, F. X., & Hutton, G. J. (2019) · Biomedicines · doi:10.3390/biomedicines7020026 · Cited by 61
“Additionally, other studies have demonstrated the presence of NPC in some chronically demyelinated lesions [91].”
BackgroundMyelin transcription factor 1 (Myt1) expression in demyelinated lesions of rodent and human CNS
Vana, A. C., Lucchinetti, C. F., Le, T. Q., & Armstrong, R. C. (2007) · Glia · doi:10.1002/glia.20492 · Cited by 52
“the reported differences of immature OP populations (Chang et al., 2002; Maeda et al., 2001).”
BackgroundIntracellular alpha-synuclein affects early maturation of primary oligodendrocyte progenitor cells
Ettle, B., Reiprich, S., Deusser, J., Schlachetzki, J. C. M., Xiang, W., Prots, I., Masliah, E., Winner, B., Wegner, M., & Winkler, J. (2014) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2014.06.012 · Cited by 57
“It is very likely that recruitment, proliferation, or maturation of OPCs is disturbed in MS, an autoimmune disease with pronounced inflammation and focal demyelination (Chang et al., 2002).”
BackgroundPetratos, S., Gonzales, M. F., Azari, M. F., Marriott, M., Minichiello, R. A., Shipham, K. A., Profyris, C., Nicolaou, A., Boyle, K., Cheema, S. S., et al. (2004) · Glia · doi:10.1002/glia.20056 · Cited by 57
“E), a sulfated chondroitin proteoglycan that has been reported to identify oligodendroglial progenitors (Nishiyama et al., 1999; Chang et al., 2000, 2002; Watanabe et al., 2002).”
BackgroundInfluentialWnt Signaling in Remyelination in Multiple Sclerosis: Friend or Foe?
Xie, C., Li, Z., Zhang, G., & Guan, Y. (2013) · Molecular Neurobiology · doi:10.1007/s12035-013-8584-6 · Cited by 65
“Remyelination is a complex and continuous process involving OPC recruitment, proliferation, and differentiation to mature OLs, as well as OL contact with axons and regenerating myelin [73–75].”
BackgroundMatsusue, Y., Horii-Hayashi, N., Kirita, T., & Nishi, M. (2014) · Journal of Histochemistry & Cytochemistry · doi:10.1369/0022155413517700 · Cited by 55
“It has been reported that NG2-IR oligodendrocyte progenitors are also present in MS lesions (Chang et al. 2002).”
BackgroundMyelin Regeneration in Multiple Sclerosis: Targeting Endogenous Stem Cells
Huang, J. K., Fancy, S. P. J., Zhao, C., Rowitch, D. H., ffrench‐Constant, C., & Franklin, R. J. M. (2011) · Neurotherapeutics · doi:10.1007/s13311-011-0065-x · Cited by 63
“This age-associated decline in remyelination resembles and may be in part a determinant of a now well-recognized feature of many chronically demyelinated MS lesions, which are replete with oligodendrocyte lineage cells that are unable to differentiate into myelinating oligodendrocytes [36–39].”
BackgroundSpecification of Optic Nerve Oligodendrocyte Precursors by Retinal Ganglion Cell Axons
Gao, L., & Miller, R. H. (2006) · Journal of Neuroscience · doi:10.1523/jneurosci.0855-06.2006 · Cited by 57
“In the adult CNS the recruitment of OPCs from adult neural stem cells may depend on local axonal cues, and loss of axonal integrity (Chang et al., 2002) may contribute to the ultimate failure of myelin repair in some MS lesions.”
BackgroundHu, Q., Ma, Q., Gennarini, G., & Xiao, Z. (2006) · Developmental Neuroscience · doi:10.1159/000090750 · Cited by 69
“Evidence has shown that this is not due to loss or inadequate numbers of OPCs at lesion loci [Wolswijk, 1998; Chang et al., 2002], but rather to inability of OPCs to differentiate into myelinating OLs.”
BackgroundEarly Distal Axonopathy of the Visual Pathway in Experimental Diabetes
Fernandez, D. C., Pasquini, L. A., Dorfman, D., Marcos, H. J. A., & Rosenstein, R. E. (2011) · American Journal Of Pathology · doi:10.1016/j.ajpath.2011.09.018 · Cited by 63
“OL progenitor cells in the lesion, for unknown reasons, gradually lose the ability to form myelinating OLs.”
Small-Molecule Klotho Enhancers As Novel Treatment Of Neurodegeneration
Abraham, C. R., Chen, C., Cuny, G. D., Glicksman, M. A., & Zeldich, E. (2012) · Future Medicinal Chemistry · doi:10.4155/fmc.12.134 · Cited by 57
Actomyosin contractility controls cell surface area of oligodendrocytes
Kippert, A., Fitzner, D., Helenius, J. H., & Simons, M. (2009) · BMC Cell Biology · doi:10.1186/1471-2121-10-71 · Cited by 62
“In multiple sclerosis remyelination can be extensive, however, OPC frequently fail to differentiate [38-41].”
BackgroundYu, H., Fei, J., Chen, X.-S., Cai, Q., Liu, H., Liu, G., & Yao, Z. (2010) · Neuroscience Letters · doi:10.1016/j.neulet.2010.03.079 · Cited by 57
Adult mesenchymal stem cell therapy for myelin repair in Multiple Sclerosis
Rivera, F. J., & Aigner, L. (2012) · Biological Research · doi:10.4067/s0716-97602012000300007 · Cited by 53
“…OPCs (Niehaus et al., 2000), the majority of data supports a failure of OPC differentiation and maturation in MS. OPCs are typically found in demyelinated areas, but they fail to diff erentiate and to remyelinate (Chang et al., 2002; Kuhlmann et al., 2008; Reynolds et al., 2002; Wolswijk, 1998).”
Caillava, C., Vandenbosch, R., Jablonska, B., Deboux, C., Spigoni, G., Gallo, V., Malgrange, B., & Baron-Van Evercooren, A. (2011) · Journal of Cell Biology · doi:10.1083/jcb.201004146 · Cited by 48
“…quantified using the FV10-ASW software (Olympus) and cell counts were expressed as the number of cells per volume (104 µm3) of CC. Statistical analysis was performed using unpaired two-tailed t test (Prism software, version 4.00; GraphPad Software Inc.). fully differentiate (Chang et al., 2002).”
InfluentialRegulator of oligodendrocyte maturation, miR-219, a potential biomarker for MS
Bruinsma, I. B., van Dijk, M., Bridel, C., van de Lisdonk, T., Haverkort, S. Q., Runia, T. F., Steinman, L., Hintzen, R. Q., Killestein, J., Verbeek, M. M., et al. (2017) · Journal of Neuroinflammation · doi:10.1186/s12974-017-1006-3 · Cited by 55
“Although large numbers of OPCs are present in MS lesions, remyelination fails, possibly caused by the inability of OPCs to differentiate into mature myelin-forming cells [6, 7].”
BackgroundLaflamme, N., Cisbani, G., Préfontaine, P., Srour, Y., Bernier, J., St-Pierre, M.-K., Tremblay, M.-È., & Rivest, S. (2018) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2018.00178 · Cited by 55
“Promoting remyelination while preventing demyelination is thus an important challenge in the course of finding a cure for the disease (Chang et al., 2002; Plemel et al., 2017).”
BackgroundDynamic response of microglia/macrophage polarization following demyelination in mice
Chu, T., Zhang, Y. P., Tian, Z., Ye, C., Zhu, M., Shields, L. B. E., Kong, M., Barnes, G. N., Shields, C. B., & Cai, J. (2019) · Journal of Neuroinflammation · doi:10.1186/s12974-019-1586-1 · Cited by 58
Thomason, E. J., Escalante, M., Osterhout, D. J., & Fuss, B. (2020) · Glia · doi:10.1002/glia.23735 · Cited by 51
Baror, R., Neumann, B., Segel, M., Chalut, K. J., Fancy, S. P. J., Schafer, D. P., & Franklin, R. J. M. (2019) · Glia · doi:10.1002/glia.23612 · Cited by 54
Tocopherol Derivative TFA-12 Promotes Myelin Repair in Experimental Models of Multiple Sclerosis
Blanchard, B., Heurtaux, T., Garcia, C., Moll, N. M., Caillava, C., Grandbarbe, L., Klosptein, A., Kerninon, C., Frah, M., Coowar, D., et al. (2013) · Journal of Neuroscience · doi:10.1523/jneurosci.0774-13.2013 · Cited by 51
“However, in most cases, remyelination fails, resulting in irreversible neurological disability (Chang et al., 2002).”
BackgroundOligodendrogenesis from neural stem cells: Perspectives for remyelinating strategies
Grade, S., Bernardino, L., & Malva, J. O. (2013) · International Journal of Developmental Neuroscience · doi:10.1016/j.ijdevneu.2013.01.004 · Cited by 54
“…molecules in OPCs migration during development and in active MS lesions; (b) quiescence of available OPCs in the lesion site, being unable to differentiate (Wolswijk, 1998); (c) or failure of the available and mature oligodendrocytes to accomplish remyelination of axons (Chang et al., 2002).”
BackgroundDrug discovery for remyelination and treatment of MS
Cole, K. L. H., Early, J. J., & Lyons, D. A. (2017) · Glia · doi:10.1002/glia.23166 · Cited by 50
“This is based on the observation that many MS lesions contain OPCs in sufficient abundance, but that there is an apparent failure of these cells to differentiate into oligodendrocytes (Chang et al., 2002; Kuhlmann et al., 2008; Lucchinetti et al., 1999; Ozawa et al., 1994; Wolswijk, 1998).”
BackgroundSeifert, T., Bauer, J., Weissert, R., Fazekas, F., & Storch, M. K. (2005) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/64.5.404 · Cited by 52
“In line with this notion are results from a recent study of chronic MS lesions that demonstrated that premyelinating oligo-dendrocytes are present within the lesion but are unable to remyelinate (47).”
ResultKhodanovich, M., Pishchelko, A., Glazacheva, V., Pan, E., Akulov, A., Svetlik, M., Tyumentseva, Y., Anan’ina, T., & Yarnykh, V. (2019) · Cells · doi:10.3390/cells8101204 · Cited by 53
“models may be more relevant to chronic MS lesions in humans, where complete remyelination usually does not happen [1,6,7].”
BackgroundResistance of human adult oligodendrocytes to AMPA/kainate receptor-mediated glutamate injury
Wosik, K. (2004) · Brain · doi:10.1093/brain/awh302 · Cited by 54
“Furthermore , the capacity for neuronal directed injury by glutamate is well established and thus this mediator may be particularly relevant for this component of the injury process (Chang et al., 2002).”
BackgroundCalzà, L., Fernández, M., Giuliani, A., D’Intino, G., Pirondi, S., Sivilia, S., Paradisi, M., DeSordi, N., & Giardino, L. (2005) · Brain Research Reviews · doi:10.1016/j.brainresrev.2004.12.022 · Cited by 56
“There are many possible speculative explanations of re-myelination failure in MS [38,76], including quantitatively inadequate recruitment and/or differentiation of OPCs [74]; axons not receptive to remyelination [30]; inappropriate support of growth factors by astrocytes and/or other inflammatory cells [67]; and unfav…”
BackgroundSun, X., Liu, Y., Liu, B., Xiao, Z., & Zhang, L. (2012) · Experimental Neurology · doi:10.1016/j.expneurol.2012.07.011 · Cited by 52
“A common cause of remyelination failure in MS patients is not an absence of OPCs (these are often present in abundance) but a failure of OPCs to differentiate into remyelinating oligodendrocytes (Chang et al., 2002; Kuhlmann, et al., 2008; Wolswijk, 1998).”
Vitamina D y remielinización en la esclerosis múltiple
Matías‐Guiu, J., Oreja‐Guevara, C., Matias-Guiu, J. A., & Gómez‐Pinedo, U. (2016) · Neurología · doi:10.1016/j.nrl.2016.05.001 · Cited by 54
Liu, S., Ren, C., Qu, X., Wu, X., Dong, F., Chand, Y. K., Fan, H., Yao, R., & Geng, D. (2017) · European Journal of Neuroscience · doi:10.1111/ejn.13485 · Cited by 51
“It was recently reported that the clinical symptom in MS may be relieved by remyelination (Chang et al., 2002; Hartley et al., 2014; Harlow et al., 2015).”
BackgroundFocal adhesion kinase (FAK): A regulator of CNS myelination
Forrest, A. D., Beggs, H. E., Reichardt, L. F., Dupree, J. L., Colello, R. J., & Fuss, B. (2009) · Journal of Neuroscience Research · doi:10.1002/jnr.22022 · Cited by 51
“Impairment of these steps of oligodendrocyte maturation appears to be responsible for, at least in part, the limited repair of the myelin sheath seen in lesions of patients suffering from the major demyelinating disease in humans: multiple sclerosis (Chang et al., 2002; Franklin and ffrench-Constant, 2008; Kuhlmann et…”
BackgroundMichel, K., Zhao, T., Karl, M. T., Lewis, K., & Fyffe-Maricich, S. L. (2015) · Journal of Neuroscience · doi:10.1523/jneurosci.4380-14.2015 · Cited by 52
Remyelination in multiple sclerosis: Cellular mechanisms and novel therapeutic approaches
Olsen, J. A., & Akirav, E. M. (2015) · Journal of Neuroscience Research · doi:10.1002/jnr.23493 · Cited by 48
“Several explanations for this limitation include a depletion of available OPCs resulting from extensive rounds of remyelination, axonal damage resulting in an inability to associate with myelin (Chang et al., 2002), and formation of glial scars (Fawcett and Asher, 1999) that might impede migration of OPCs to demyelina…”
BackgroundInfluentialRelationship between cell cycle molecules and onset of oligodendrocyte differentiation
Casaccia‐Bonnefil, P., & Liu, A. (2003) · Journal of Neuroscience Research · doi:10.1002/jnr.10565 · Cited by 55
“…CNS as a population of slowly dividing cells (Ffrench-Constant and Raff, 1986; Wolswijk and Noble, 1989; Reynolds and Hardy, 1997) and are thought to be responsible for remyelination after injury (Gensert and Goldman, 1997; Blakemore and Keirstead, 1999; Chang et al., 2000, 2002; Franklin, 2002).”
BackgroundOligodendrocyte Precursors on the Move: Mechanisms Directing Migration
Jarjour, A. A., & Kennedy, T. E. (2004) · The Neuroscientist · doi:10.1177/1073858403260751 · Cited by 59
Neuropathology of Multiple Sclerosis
Popescu, B. F. G., & Lucchinetti, C. F. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-800763-1.00009-9 · Cited by 52
Pentón-Rol, G., Marín-Prida, J., & Falcón-Cama, V. (2018) · Behavioral Sciences · doi:10.3390/bs8010015 · Cited by 50
“Using autopsy samples from MS patients, OPCs have been found in chronically demyelinated lesions, with a density similar to those in the developing rodent brain but unable to sheathe the injured dystrophic and swelled axons [35].”
BackgroundAntibody-mediated neutralization of myelin-associated EphrinB3 accelerates CNS remyelination
Syed, Y. A., Zhao, C., Mahad, D., Möbius, W., Altmann, F., Foss, F., Sentürk, A., Acker-Palmer, A., Lubec, G., Lilley, K., et al. (2016) · Acta Neuropathologica · doi:10.1007/s00401-015-1521-1 · Cited by 50
“Failure of CNS remyelination in MS lesions has been associated with a poorly understood inability of OPCs to differentiate into myelin-forming oligodendrocytes [11, 32].”
BackgroundPervasive environmental chemicals impair oligodendrocyte development
Cohn, E. F., Clayton, B. L. L., Madhavan, M., Lee, K. A., Yacoub, S. G., Federov, Y., Scavuzzo, M. A., Friedman, K. P., Shafer, T. J., & Tesar, P. J. (2024) · Nature Neuroscience · doi:10.1038/s41593-024-01599-2 · Cited by 53
Molecular and immunogenic features of myelin lipids: incitants or modulators of multiple sclerosis?
Podbielska, M., & Hogan, E. (2009) · Multiple Sclerosis Journal · doi:10.1177/1352458509106708 · Cited by 47
“One speculation is that anti-GD1a antibodies within the demyelinated MS lesion impair maturation of oligodendrocyte precursors and remyelination [66], effects associated with MS progression [67].”
BackgroundCell Therapy for Multiple Sclerosis
Ben‐Hur, T. (2011) · Neurotherapeutics · doi:10.1007/s13311-011-0073-x · Cited by 51
“relative to normal white matter [39, 76–78].”
Therapeutic applications of oligodendrocyte precursors derived from human embryonic stem cells
Sharp, J., & Keirstead, H. S. (2007) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2007.10.006 · Cited by 55
Olig1 is expressed in human oligodendrocytes during maturation and regeneration
Othman, A. H., Frim, D. M., Polak, P. E., Vujicic, S., Arnason, B. G. W., & Boullerne, A. I. (2011) · Glia · doi:10.1002/glia.21163 · Cited by 54
“In MS lesions, OPC initiate differentia- tion by extending processes and contacting denuded axons, but they are inhibited to accomplish the final stage of myelin ensheathment (Chang et al., 2002; Kuhlmann et al., 2008).”
BackgroundInfluentialDynamics and heterogeneity of brain damage in multiple sclerosis
Kotelnikova, E. A., Kiani, N. A., Abad, E. M., Martínez‐Lapiscina, E. H., Andorrà, M., Zubizarreta, I., Valdeolivas, I. P., Pertsovskaya, I., Alexopoulos, L. G., Olsson, T. P., et al. (2017) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1005757 · Cited by 56
Dulămea, A. O. (2017) · Neural Regeneration Research · doi:10.4103/1673-5374.221146 · Cited by 54
“Thus, OPCs were identified within active MS lesions but their number and capacity to differentiate decreases with disease duration and OPCs were more vulnerable to injury mediators than OLs (Chang et al., 2002).”
BackgroundZheng, W., Li, Q., Zhao, C., Da, Y., Zhang, H., & Chen, Z. (2018) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2018.00239 · Cited by 56
Restoration of FcRγ/Fyn signaling repairs central nervous system demyelination
Seiwa, C., Yamamoto, M., Tanaka, K., Fukutake, M., Ueki, T., Takeda, S., Sakai, R., Ishige, A., Watanabe, K., Akita, M., et al. (2007) · Journal of Neuroscience Research · doi:10.1002/jnr.21196 · Cited by 56
“Although the reasons for the eventual failure of remyelination in MS are unknown, the presence of OPCs and immature oligodendrocytes in some nonrepairing lesions suggests that these cells fail to drive relevant differentiation signal machinery (Wolswijk, 1998; Chang et al., 2002; Back et al., 2005).”
BackgroundExpression of gangliosides on glial and neuronal cells in normal and pathological adult human brain
Marconi, S., Toni, L. D., Lovato, L., Tedeschi, E., Gaetti, L., Acler, M., & Bonetti, B. (2005) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2005.03.025 · Cited by 50
Mohan, H., Friese, A., Albrecht, S., Krumbholz, M., Elliott, C. L., Arthur, A., Menon, R., Farina, C., Junker, A., Stadelmann, C., et al. (2014) · Acta Neuropathologica Communications · doi:10.1186/s40478-014-0168-9 · Cited by 49
“The presence of OPCs and premyelinating oligodendrocytes in many demyelinated lesions [13,14] suggests that this could be caused by failure of OPC to differentiate into myelinating oligodendrocytes.”
BackgroundLiu, J.-Q., Carl, J. W., Joshi, P. S., Ray‐Chaudhury, A., Pu, X.-A., Shi, F., & Bai, X. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.178.10.6227 · Cited by 49
Axonal damage in multiple sclerosis: a complex issue in a complex disease
Grigoriadis, N., Ben‐Hur, T., Karussis, D. M., & Milonas, I. A. (2004) · Clinical Neurology and Neurosurgery · doi:10.1016/j.clineuro.2004.02.017 · Cited by 54
“[55] Chang A, Tourtellotte W, Rudick R, Trapp B.”
BackgroundQin, J., Sikkema, A. H., van der Bij, K., de Jonge, J. C., Klappe, K., Nies, V. J. M., Jonker, J. W., Kok, J., Hoekstra, D., & Baron, W. (2017) · Journal of Neuroscience · doi:10.1523/jneurosci.0103-17.2017 · Cited by 49
“For example, in MS lesions, a significant fraction of OPCs remains quiescent (Lucchinetti et al., 1999; Chang et al., 2002; Kuhlmann et al., 2008), among others due to the presence of Fn aggregates (Stoffels et al.”
BackgroundInfluentialQuantitative spinal cord MRI in radiologically isolated syndrome
Leon, P. A., Cybulsky, K., Sankar, S., Casserly, C. S., Leung, G., Hohol, M. J., Selchen, D. H., Montalbán, X., Bharatha, A., & Oh, J. (2018) · Neurology Neuroimmunology & Neuroinflammation · doi:10.1212/nxi.0000000000000436 · Cited by 50
“%) is higher than previously reported (30%–42%).2,36,37 This is likely due to our use of a novel sequence that is T1-weighted for cervical SC lesion detection (PSIR), which has shown to be 46%more sensitive than conventional sagittal T2-based sequences for the detection of cervical SC lesions.38 Adequate detection of…”
ResultInfluentialConnexin 43 deletion in astrocytes promotes CNS remyelination by modulating local inflammation
Li, T., Niu, J., Yu, G., Ezan, P., Yi, C., Wang, X., Koulakoff, A., Gao, X., Chen, X., Sáez, J. C., et al. (2019) · Glia · doi:10.1002/glia.23770 · Cited by 51
“In clinical specimens of demyelinating diseases such as multiple sclerosis (MS), lack of remyelination is mainly attributed to the inhibition of OPC differentiation (Chang et al., 2002; Kuhlmann et al., 2008).”
BackgroundEvonuk, K. S., Doyle, R. E., Moseley, C. E., Thornell, I. M., Adler, K., Bingaman, A. M., Bevensee, M. O., Weaver, C. T., Min, B., & DeSilva, T. M. (2020) · Science Advances · doi:10.1126/sciadv.aax5936 · Cited by 51
“Another study illustrated differentiated oligodendrocytes in lesion sites that do not appear to form mature myelin, surmising an interruption in maturation (49).”
BackgroundScalabrino, G. (2022) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-020-00989-x · Cited by 47
Antidepressants on Multiple Sclerosis: A Review of In Vitro and In Vivo Models
Stamoula, Ε., Siafis, S., Dardalas, I., Ainatzoglou, A., Matsas, A., Athanasiadis, T., Sardeli, C., Stamoulas, K., & Papazisis, G. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.677879 · Cited by 48
“In MS patients, demyelination is often accompanied by compensatory remyelinating activity, an effect that is principally mediated by oligodendrocyte maturation (75).”
BackgroundNatural history of multiple sclerosis: implications for counselling and therapy
Confavreux, C., & Vukusic, S. (2002) · Current Opinion in Neurology · doi:10.1097/00019052-200206000-00006 · Cited by 55
Heterogeneity and regulation of oligodendrocyte morphology
Osanai, Y., Yamazaki, R., Shinohara, Y., & Ohno, N. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.1030486 · Cited by 51
“Morphological three dimensional analysis using immunohistochemistry and confocal microscopy showed that oligodendrocytes in chronic lesions extended multiple processes and contacted demyelinated axons but failed to remyelinate those axons (Chang et al., 2002).”
MethodJiang, S., Ballerini, P., Buccella, S., Giuliani, P., Jiang, C., Huang, X., & Rathbone, M. P. (2008) · Purinergic Signalling · doi:10.1007/s11302-007-9093-8 · Cited by 53
rHIgM22 enhances remyelination in the brain of the cuprizone mouse model of demyelination
Mullin, A. P., Cui, C., Wang, Y., Wang, J., Troy, E., Caggiano, A. O., Parry, T. J., Colburn, R. W., & Pavlopoulos, E. (2017) · Neurobiology of Disease · doi:10.1016/j.nbd.2017.05.015 · Cited by 48
Cell Type-Specific Intralocus Interactions Reveal Oligodendrocyte Mechanisms in MS
Factor, D. C., Barbeau, A. M., Allan, K. C., Hu, L. R., Madhavan, M., Hoang, A. T., Hazel, K. E. A., Hall, P. A., Nisraiyya, S., Najm, F. J., et al. (2020) · Cell · doi:10.1016/j.cell.2020.03.002 · Cited by 46
Fibroblast growth factor 2 induces loss of adult oligodendrocytes and myelin in vivo
Butt, A. M., & Dinsdale, J. (2005) · Experimental Neurology · doi:10.1016/j.expneurol.2004.11.007 · Cited by 55
Physiopathology of symptoms and signs in multiple sclerosis
Sá, M. J. (2012) · Arquivos de Neuro-Psiquiatria · doi:10.1590/s0004-282x2012000900016 · Cited by 63
The endocannabinoid 2-AG enhances spontaneous remyelination by targeting microglia
Mecha, M., Yanguas-Casás, N., Feliú, A., Mestre, L., Carrillo-Salinas, F., Azcoitia, I., Yong, V. W., & Guaza, C. (2019) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2018.12.013 · Cited by 47
“, 2017), or their maturation is frozen in a premyelinating state in which the oligodendrocytes contact and ensheath the axons but without forming compact myelin (Chang et al., 2002).”
Olejnik, P., Roszkowska, Z., Adamus, S., & Kasarełło, K. (2024) · Pharmacological Reports · doi:10.1007/s43440-024-00642-0 · Cited by 54
“Therefore, remyelination is influenced not only by the availability of oligodendrocyte progenitor cells and their capacity to differentiate into oligodendrocytes but also by additional factors that may affect the regeneration of the myelin sheath [106].”
Myelin dysfunction in aging and brain disorders: mechanisms and therapeutic opportunities
Huang, Z., Zhang, Y., Zou, P., Zong, X., & Zhang, Q. (2025) · Molecular Neurodegeneration · doi:10.1186/s13024-025-00861-w · Cited by 53
“Despite the presence of OPCs in lesional regions, mature oligo-dendrocytes are significantly reduced or even absent in these areas [146, 147].”
Prospects of Cell Therapy for Disorders of Myelin
Ben‐Hur, T., & Goldman, S. A. (2008) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1444.014 · Cited by 47
The Transcriptional Activator Krüppel-like Factor-6 Is Required for CNS Myelination
Laitman, B. M., Asp, L., Mariani, J. N., Zhang, J., Liu, J., Sawai, S., Chapouly, C., Horng, S. H., Kramer, E. G., Mitiku, N., et al. (2016) · PLoS Biology · doi:10.1371/journal.pbio.1002467 · Cited by 50
The landscape of targets and lead molecules for remyelination
Caprariello, A. V., & Adams, D. (2022) · Nature Chemical Biology · doi:10.1038/s41589-022-01115-2 · Cited by 48
Huang, J. K., & Franklin, R. J. M. (2011) · Neurochemistry International · doi:10.1016/j.neuint.2011.01.017 · Cited by 49
The role of growth factors as a therapeutic approach to demyelinating disease
Huang, Y., & Dreyfus, C. F. (2016) · Experimental Neurology · doi:10.1016/j.expneurol.2016.02.023 · Cited by 47
“…that are demyelinated contain progenitor cells or premyelinating oligodendrocytes, suggesting an inability to differentiate, while approximately 30% of lesions contain few progenitors, suggesting an inability to migrate to the lesion site (Boyd et al 2013, Chang et al 2002, Lucchinetti et al 1999).”
BackgroundTIMP-1 Promotes Oligodendrocyte Differentiation Through Receptor-Mediated Signaling
Nicaise, A. M., Johnson, K. M., Willis, C. M., Guzzo, R. M., & Crocker, S. J. (2019) · Molecular Neurobiology · doi:10.1007/s12035-018-1310-7 · Cited by 45
Tiane, A., Schepers, M., Riemens, R. J. M., Rombaut, B., Vandormael, P., Somers, V. A., Prickaerts, J., Hellings, N., van den Hove, D., & Vanmierlo, T. (2021) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-021-03927-2 · Cited by 50
Overcoming failure to repair demyelination in EAE: γ-secretase inhibition of Notch signaling
Juryńczyk, M., Jurewicz, A., Bielecki, B., Raine, C. S., & Selmaj, K. W. (2007) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2007.09.007 · Cited by 51
Mozafari, S., Starost, L., Manot-Saillet, B., Garcia-Diaz, B., Xu, Y. K. T., Roussel, D., Levy, M. J. F., Ottoboni, L., Kim, K.-P., Schöler, H. R., et al. (2020) · Science Advances · doi:10.1126/sciadv.abc6983 · Cited by 45
Remyelination and Multiple Sclerosis: Therapeutic Approaches and Challenges
Hartley, M. D., Altowaijri, G., & BOURDETTE, D. N. (2014) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-014-0485-1 · Cited by 50
Karttunen, M. J., Czopka, T., Goedhart, M., Early, J. J., & Lyons, D. A. (2017) · PLOS ONE · doi:10.1371/journal.pone.0178058 · Cited by 45
Emerging Cellular and Molecular Strategies for Enhancing Central Nervous System (CNS) Remyelination
Abu-Rub, M., & Miller, R. H. (2018) · Brain Sciences · doi:10.3390/brainsci8060111 · Cited by 50
“Moreover, the differentiation of OPCs into myelinating oligodendrocytes is also impaired in chronic and progressive forms of MS [70,71].”
Background
Metadata
- Authors
- Chang, A., Tourtellotte, W. W., Rudick, R., & Trapp, B. D.
- Affiliations
- Cleveland Clinic (US)
- VA West Los Angeles Medical Center (US)
- Cleveland Clinic Research (US)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2002-01-17
- Volume
- 346
- Issue
- 3
- Pages
- 165-173
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2058358434
- Cited by
- 991
- References
- 39
- Citations by year
- 2026: 19 · 2025: 25 · 2024: 42 · 2023: 38 · 2022: 32 · 2021: 34 · 2020: 36 · 2019: 57 · 2018: 43 · 2017: 52 · 2016: 44 · 2015: 55 · 2014: 44 · 2013: 50 · 2012: 40
- FWCI
- 26.66
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute of Neurological Disorders and Stroke (R01 NS35058, P01NS038667, R01NS035058, P01-NS-38667)
- Topics
- Health Sciences › Medicine › Clinical Neurology › Multiple Sclerosis Research Studies
- Life Sciences › Neuroscience › Developmental Neuroscience › Neurogenesis and neuroplasticity mechanisms
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Mesenchymal stem cell research
- Keywords
- multiple sclerosis, remyelination, chronic lesions, demyelinated axons, oligodendrocyte precursor cells, disease duration
- MeSH terms
- Chondroitin Sulfate Proteoglycan 4, Adult, Aged, Antigens, Axons, Brain, Brain Chemistry, Female, Humans, Male, Middle Aged, Multiple Sclerosis, Nerve Fibers, Myelinated, Oligodendroglia, Proteoglycans, Stem Cells, Microscopy, Confocal
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.